Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Science of MDHAQ/RAPID3 Scores

Theodore Pincus, MD  |  Issue: December 2011  |  December 12, 2011

click for large version
Figure 7: Survival more than five years in the general population older than age 50 years in Finland.

The strength of the biomedical model paradigm may account in large part for limited incorporation of patient self-report data concerning physical function into usual rheumatology care.28 Hypertension and diabetes were transformed to aggressive public health matters through documentation that “tight control” and “treat-to-target” of blood pressure or hemoglobin A1c level led decreased mortality rates. Similarly, it seemed important to document whether reduction of abnormal physical function scores through “treat-to-target” could reduce or even eliminate premature mortality in RA. Achieving this goal requires long-term observational studies since, ethically, clinical trials could not be conducted in a symptomatic disease such as RA over long periods (unlike asymptomatic conditions such as hypertension or hypercholesterolemia).36 However, most rheumatology reports continue to emphasize changes in radiographic and laboratory measures that have far lower significance in the prognosis of RA mortality than self-report questionnaire scores.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A few other rheumatologists have collected clinical databases since the 1980s, generally superior to mine—Fred Wolfe, MD in Wichita; Rolf Rau, MD, in Ratingen, Germany; Tore Kvien, MD, in Oslo, Norway; and Tuulikki Sokka, MD, PhD, in Jyvaskyla, Finland—to pursue “evidence-based” usual rheumatology care. I am grateful to each for their friendship and observations, which often confirmed or anteceded novel, unexpected results, indicating the value of data collection in usual care. Nonetheless, most rheumatology visits are conducted largely as they were 50 years ago when I started in rheumatology as a student—albeit many doctors are typing into an electronic medical record (EMR) instead of writing or dictating.

The Future of MDHAQ

Further developments of the MDHAQ currently in progress include: 1) an electronic version, with automated scoring and entry into a database; 2) report from the four-page MDHAQ in a standard medical history format, entirely from self-report, with no data entry or dictation or typing by the doctor; 3) methods for storage of the medical history data for both doctors and patients, which include the capacity to amend and correct stored information; and 4) integration of MDHAQ/RAPID3 into EMRs, a particularly difficult challenge in view of many incompatible systems, but one that has been solved in some settings. An MDHAQ/RAPID3 in usual care in no way prevents collecting a DAS28, CDAI, ultrasound, or any other measure and assures quantitative data at each visit.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

As someone who has conducted basic laboratory investigation and supervised a clinical laboratory, I have found self-reports from questionnaires provide data that are as scientifically valid as laboratory assays, and can provide key information to facilitate patient management and improve outcome. I hope that more health professionals will adopt “evidence-based” approaches to improve patient outcomes. Readers are invited to contact me to help implement an MDHAQ/RAPID3 in their clinic settings.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:Diagnostic Criteriaevidence-based medicineHealth Assessment Questionnairepatient carerheumatology

Related Articles

    Remote Use of the Multidimensional Health Assessment Questionnaire (MDHAQ)

    December 18, 2019

    The patient medical history is far more prominent in clinical decisions for rheumatology than for many common chronic diseases in which a gold standard biomarker, such as blood pressure or serum glucose, is applicable to diagnosis and management of all individual patients.1 Components of a subjective patient history may be recorded as structured, quantitative, standard,…

    The Peripatetitc Theodore Pincus, MD

    July 1, 2007

    Tireless champion for patient self-report

    Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?

    April 1, 2013

     Long-term, low-dose prednisone at less than 5 mg/day appears tolerable and effective for many patients with rheumatoid arthritis (RA)

    Glucocorticoid Use in Rheumatoid Arthritis Management Focus of Ongoing Debate

    March 1, 2015

    Questions around prescribing steroids as bridge therapy, in long-term low dosages, or low-dose timed-release formulas, or not at all evoke controversy among rheumatologists

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences